A

Astrazeneca Pharma

(NSE: ASTRAZEN)

ASTRAZEN

3039.9

0.00 (0.00%)

Astrazeneca Pharma Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Astrazeneca Pharma Price Chart

Note: The data used to display charts is delayed by 15 mins as per guidelines.

Astrazeneca Pharma Price Summary

Today High

3104.75

Today Low

2945.8

52 Week High

3104.75

52 Week Low

2945.8

Astrazeneca Pharma Fundamentals

Market Cap

6860.9 Cr

CASA

0.0

No. Of Shares

2.5 Cr

P/E

80.7

P/B

16.6

Face Value

2.0

Dividend Yeild

0.1

Book Value

181.8

Net Interest Income

104.6

Cost to Income

NA

Promoter Holdings

75.0

EPS

37.3

CAR

NA

ROE

22.8

ROCE

31.2

Profit Growth

NA

Astrazeneca Pharma Peer Comparison

COMPANY

PRICE

MCAP (cr)

P/B

P/E

EPS

ROE

ROCE

NII

Astrazeneca Pharma

3039.9

6860.9 Cr

16.6

80.7

37.3

22.8

31.2

104.6

Granules India

317.35

6879.7 Cr

3.5

13.6

22.3

28.0

26.5

1.3K

P&G Health

3954.65

7325.6 Cr

13.3

52.5

106.5

22.0

29.1

1.5K

Jubilant Pharmova

328.3

7326.1 Cr

8.5

50.5

13.5

11.0

11.8

57.0

Glenmark Life

384.8

5869.7 Cr

0.0

0.0

358.8

60.9

96.8

4.3

Jubilant Ingrevia

490.05

7915.5 Cr

2.6

107.8

2.4

4.9

5.6

4.2

FAQ’s on Astrazeneca Pharma

About Astrazeneca Pharma

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.

Trade Astrazeneca Pharma today

Create a free portfolio in Trinkerr and earn and grow along with peers